Destiny Pharma (LON:DEST) Trading Down 30.1% – Time to Sell?

Destiny Pharma plc (LON:DEST) shares fell 30.1% during trading on Wednesday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). 4,179,453 shares traded hands during trading, an increase of 484% from the average session volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.06).

Analysts Set New Price Targets

Separately, Shore Capital reissued a “house stock” rating on shares of Destiny Pharma in a report on Monday, July 15th.

Destiny Pharma Trading Down 30.1 %

The business’s 50-day simple moving average is GBX 3 and its 200-day simple moving average is GBX 8.92. The company has a market capitalization of £2.87 million, a PE ratio of -50.00 and a beta of 0.22.

Destiny Pharma Company Profile

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.